Health CarePharmaceuticals and Biotechnology
  • Price (CHF)67.45
  • Today's Change1.10 / 1.66%
  • Shares traded75.09k
  • 1 Year change-38.23%
  • Beta1.0425
Data delayed at least 15 minutes, as of Jul 01 2022 16:30 BST.
More ▼
Take Action
Take Action
Add this security to watchlist, portfolio, or create an alert to track market movement

Profile data is unavailable for this security.

About the company

Bachem Holding AG is a Switzerland-based biochemical company that provides services to the pharmaceutical and biotechnology industry. The Company focuses on the process development and manufacturing of peptides and organic molecules as active pharmaceutical ingredients (APIs), as well as on the development of biochemical products for research purposes. Its product portfolio comprises fluorescent dyes for the fluorescence energy transfer (FRET) analysis of receptor-ligand interactions, protein-protein interactions and the cleavage of substrate molecules, as well as glycosylated peptides for the manipulation of drug properties. The Company markets products under the Bachem and Clinalfa brands and operates production facilities in Switzerland and in the United States.

  • Revenue in CHF (TTM)503.23m
  • Net income in CHF114.68m
  • Incorporated1971
  • Employees1.64k
  • Location
    Bachem Holding AGHauptstrasse 144BUBENDORF 4416SwitzerlandCHE
  • Phone+41 619352333
  • Fax+41 619352324
  • Websitehttp://www.bachem.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
(YOY change %)
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
(5 yr growth rate)
Vitrolife AB191.20m28.37m3.11bn1.17k96.942.1568.2816.292.552.5516.93114.690.18643.036.304,809,944.002.788.882.949.5559.3163.5314.9324.081.1723.180.136523.2234.9414.4518.8712.3635.349.00
Krka d.d. Novo Mesto1.60bn313.29m3.12bn11.63k9.451.497.411.9410.0510.0551.4663.710.64531.513.56139,212.3012.5811.0715.0613.2456.9857.6819.5016.242.16--0.005956.332.015.926.2623.31-9.8915.41
Virbac SA1.06bn113.24m3.13bn5.10k27.624.3119.702.9413.4013.40125.9585.820.92082.3210.18207,805.7010.005.2614.497.5447.5047.4610.867.100.955720.290.11535.3113.894.06-16.8226.713.33--
Abcam Plc366.06m4.53m3.19bn1.75k705.404.1960.098.730.0170.0171.382.870.34871.796.68180,228.600.4312--0.4979--71.21--1.24--0.818956.200.2593--------------
Laboratorios Farmaceuticos ROVI SA724.19m182.41m3.23bn1.75k17.537.5216.124.473.293.2913.067.671.081.225.53413,312.4027.2812.5637.6216.2760.7658.3125.1914.221.10324.760.145233.0454.4619.59150.7142.4617.7639.18
Richter Gedeon Vegyeszeti Gyar Nyrt1.65bn374.77m3.24bn12.17k8.621.376.551.97805.00805.003,535.435,083.670.61452.254.11--14.217.8715.958.9555.8055.9823.1313.182.42--0.017437.8211.2610.1033.3816.1031.4916.23
ALK-Abello A/S544.73m34.30m3.47bn2.57k109.447.6650.336.361.161.1618.4516.600.68921.345.891,596,374.004.34-0.51155.47-0.616361.8558.116.30-0.81180.975620.060.146--12.175.44776.00-4.103.17--
Galapagos NV558.84m-125.99m3.56bn1.31k--1.34--6.37-1.59-1.599.9340.310.1042--5.13426,634.10-2.35-2.45-2.64-2.7571.80---22.54-17.828.41--0.0095--1.5728.8659.67--64.60--
Hikma Pharmaceuticals Plc2.45bn404.02m4.17bn8.70k10.841.857.401.701.501.509.068.760.60021.723.70242,557.009.873.8013.055.2150.9650.9016.456.611.3810.350.255471.439.065.54-2.3222.123.8011.07
Evotec SE650.05m89.63m4.22bn4.35k40.823.22--6.500.58450.58453.837.410.34524.035.22154,745.404.766.815.628.4223.5827.4013.7916.623.05--0.28360.0023.3830.313,332.7850.9163.60--
Dechra Pharmaceuticals plc743.49m84.61m4.40bn1.95k52.235.9323.325.920.66970.66975.895.900.53751.907.42329,357.306.123.376.873.7956.8856.4711.386.851.7513.570.331497.7818.0419.6963.7234.3778.1817.02
H. Lundbeck A/S2.21bn149.16m4.82bn5.35k6.470.388912.972.195.585.5882.5692.860.47161.164.223,066,
BACHEM HOLDING AG503.23m114.68m4.97bn1.64k41.702.7534.769.881.621.627.1024.520.50091.305.50307,037.2011.419.8213.2012.3033.1331.4322.7919.024.17--0.018363.7625.1816.3046.9122.7218.436.96
Orion Oyj1.04bn191.53m5.99bn3.38k31.199.3225.625.741.361.367.414.550.86541.666.05310,849.5015.9018.9424.3123.8257.9259.5218.3719.891.082,397.000.1709101.61-3.44-0.613-11.87-4.8912.25-0.6537
Swedish Orphan Biovitrum AB (publ)1.56bn235.06m6.35bn1.57k26.132.7613.774.068.498.4956.5580.490.34621.334.7410,771,650.005.208.456.5010.6174.5576.4115.0321.080.66238.180.29150.001.7624.44-17.4427.3117.53--
DiaSorin SpA-100.07bn-100.07bn7.07bn3.36k--------------------------16.63--19.02--67.86--24.99------25.2440.4316.8025.4622.5825.685.59
Data as of Jul 01 2022. Currency figures normalised to Bachem Holding AG's reporting currency: Swiss Franc CHF

Institutional shareholders

11.97%Per cent of shares held by top holders
HolderShares% Held
Capital Research & Management Co. (World Investors)as of 31 Dec 20212.13m2.89%
BlackRock Investment Management (UK) Ltd.as of 31 May 20221.13m1.54%
VV Verm�gensverwaltung AGas of 29 Apr 2022977.50k1.33%
The Vanguard Group, Inc.as of 02 Jun 2022854.97k1.16%
UBS Asset Management Switzerland AGas of 31 May 2022736.72k1.00%
Norges Bank Investment Managementas of 31 Dec 2021729.50k0.99%
Abrdn Investment Management Ltd.as of 31 Dec 2021604.26k0.82%
Vontobel Asset Management AGas of 31 May 2022603.29k0.82%
Credit Suisse Asset Management (Schweiz) AGas of 31 May 2022533.19k0.72%
BlackRock Fund Advisorsas of 02 Jun 2022525.40k0.71%
More ▼
Data from 31 Dec 2021 - 29 Apr 2022Source: FactSet Research Systems Inc.
An LSEG Business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.